Universität Regensburg
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
2
Ending by 2030
Sep 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for Means and Methods for Staging, Typing and Treating a Cancerous Disease (US 11,702,701) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for An Apparatus for Sensor-Based Examination of Biological Cells (US 11,969,730) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,278,087 | Energy production with hyperthermophilic organisms In force · USPTO record | In force | USPTO record | |
| US 9,700,509 | Solutions of lipophilic substances, especially medicinal solutions In force · USPTO record | In force | USPTO record | |
| US 8,927,750 | Acyloxy- and PHOSPHORYLOXY-BUTADIENE-FE(CO)3 Complexes as Enzyme-Triggered Co-Releasing Molecules In force · High confidence | In force | High confidence | |
| US 10,106,540 | HDAC6 inhibitors and their uses In force · USPTO record | In force | USPTO record | |
| US 11,702,701 | Means and Methods for Staging, Typing and Treating a Cancerous Disease In force · High confidence | In force | High confidence | |
| US 10,895,546 | Bipolar electrode for the impedimetric examination and manipulation of living cells in vitro In force · USPTO record | In force | USPTO record | |
| US 11,578,298 | Device for the Cultivation of and Radiation-Induced Killing of Cells and Method for Analyzing a Migration And/Or Healing of a Wound In force · High confidence | In force | High confidence | |
| US 11,969,730 | An Apparatus for Sensor-Based Examination of Biological Cells In force · High confidence | In force | High confidence | |
| US 12,527,862 | Bactericidal/Permeability Increasing Protein for Use in a Method of Immunization, Preferably as an Adjuvant in a Method of Vaccination In force · High confidence | In force | High confidence | |
| US 12,478,605 | Biochanin a derivatives for treatment of BEST1-related retinopathies In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 11: 5 patents in force now held by others · 7 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
14 pending · 4 abandoned · 15 no status recorded